Mankin's 1994 NEJM editorial accompanies the landmark Brittberg et al. paper introducing autologous chondrocyte transplantation (ACT). It explains why hyaline cartilage cannot heal on its own and evaluates where ACT fits among competing cartilage repair strategies. This is a foundational reference for understanding the biological rationale behind modern cartilage restoration.
Every cartilage restoration procedure you will perform rests on the biology Mankin lays out here. Cartilage cannot heal itself because four barriers converge at once: no vascularity, no fibrinogen, proteoglycan suppression of growth factors, and a degradative enzyme cascade that outpaces any repair attempt.
When selecting patients for ACT or any cartilage restoration technique, location is decisive. Distal femoral lesions responded well (14/16 good-to-excellent). Patellar lesions failed at the same rate (5/7 no improvement) because higher joint reactive forces overwhelm the regenerating tissue.
Think of ACT as a point solution, not a systemic fix. The patient must have a solitary lesion in an otherwise normal joint. Offering it to someone with early global arthritis is the wrong application of the right tool.
The cartilage matrix's type II collagen signature on biopsy remains the gold standard for confirming true hyaline regeneration rather than fibrocartilage fill — a distinction that still drives how we interpret second-look arthroscopy and biopsy data today.
Mankin's 1994 NEJM editorial accompanies the landmark Brittberg et al. paper introducing autologous chondrocyte transplantation (ACT). It explains why hyaline cartilage cannot heal on its own and evaluates where ACT fits among competing cartilage repair strategies. This is a foundational reference for understanding the biological rationale behind modern cartilage restoration.
Every cartilage restoration procedure you will perform rests on the biology Mankin lays out here. Cartilage cannot heal itself because four barriers converge at once: no vascularity, no fibrinogen, proteoglycan suppression of growth factors, and a degradative enzyme cascade that outpaces any repair attempt.
When selecting patients for ACT or any cartilage restoration technique, location is decisive. Distal femoral lesions responded well (14/16 good-to-excellent). Patellar lesions failed at the same rate (5/7 no improvement) because higher joint reactive forces overwhelm the regenerating tissue.
Think of ACT as a point solution, not a systemic fix. The patient must have a solitary lesion in an otherwise normal joint. Offering it to someone with early global arthritis is the wrong application of the right tool.
The cartilage matrix's type II collagen signature on biopsy remains the gold standard for confirming true hyaline regeneration rather than fibrocartilage fill — a distinction that still drives how we interpret second-look arthroscopy and biopsy data today.